Obinutuzumab

Also known as Gazyva and Gazyvaro.

Latest news on obinutuzumab

15 November 2026
Genentech’s Gazyva wins first FDA approval for primary membranous nephropathy

The approval covers adults at risk of disease progression and follows Phase III results showing higher remission rates than tacrolimus.

13 November 2026
EMA recommends Gazyvaro for active systemic lupus erythematosus

The proposed add-on use targets adults whose disease remains active despite standard therapy and who test positive for specified antibodies.

13 November 2026
Roche’s Gazyva/Gazyvaro recommended for EU approval in SLE

In the phase III trial, 76.7% of treated patients achieved an SRI-4 response at 52 weeks, versus 53.5% on placebo.

15 July 2026
Roche: FDA grants Priority Review for Gazyva/Gazyvaro (obinutuzumab) in primary membranous nephropathy

Priority Review follows MAJESTY phase III showing 36.9% complete remission at two years vs 5.7% with tacrolimus; FDA decision expected by Nov 2026.

14 July 2026
Genentech’s Gazyva (obinutuzumab) granted FDA priority review for primary membranous nephropathy

FDA granted priority review for obinutuzumab in pMN after Phase III MAJESTY showed markedly higher complete remission vs tacrolimus; FDA decision expected Nov 2026.

14 May 2026
Chugai, Nippon Shinyaku file Gazyva (obinutuzumab) for idiopathic nephrotic syndrome

Phase III INShore showed improved sustained remission and steroid reduction versus MMF; no new safety signals, supporting a regulatory application.

21 April 2026
FDA accepts Roche sBLA for Gazyva/Gazyvaro in systemic lupus erythematosus (SLE)

ALLEGORY phase III: SRI‑4 response 76.7% vs 53.5% (adj diff 23.1%), doubled remission rates, fewer flares and reduced steroid use. FDA decision expected by Dec 2026.

20 April 2026
FDA Accepts Genentech sBLA for Gazyva in SLE

FDA accepted sBLA for an anti‑CD20 in SLE after Phase III ALLEGORY: SRI‑4 responders 76.7% vs 53.5%, higher remission, fewer flares and steroid reduction; decision due Dec 2026.

6 March 2026
Genentech's Gazyva Reduces Lupus Disease Activity in Phase III Trial

Gazyva shows significant improvement in SLE symptoms, achieving a 76.7% response rate and doubling remission rates in a Phase III trial, as published in NEJM.

19 February 2026
Genentech's Venclexta and Acalabrutinib Combo Approved by FDA for Untreated CLL

FDA approves all-oral, fixed-duration regimen for CLL, reducing treatment time. AMPLIFY study shows 35% lower risk of progression or death compared to chemoimmunotherapy.